TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a diagnosis of schizophrenia~* Requires acute treatment for symptoms of schizophrenia~* Willing and able to be confined to an inpatient study unit for up to 3-4 weeks~* Has experienced at least one previous hospitalization for schizophrenia~* Has been able to achieve outpatient status for more than 3 months in the past year~* Has a body mass index (BMI) between 18.0 and 40.0 kg/m\^2~* Resides in a stable living situation when not hospitalized~* Has an identified reliable caregiver (for example, family member)~* Additional criteria may apply~Exclusion Criteria:~* Poses a current suicide risk~* Pregnant, planning to become pregnant, or breastfeeding~* Initiated first antipsychotic treatment within the past 12 months~* Has received a long-acting injectable antipsychotic in the past 3 months~* Has participated in a clinical study involving any investigational product within the past 3 months, or is currently participating in a clinical study involving an investigational product.~* A positive urine drug test for drugs of abuse~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Type: EXPERIMENTAL): Regular injections
- Treatment Group 2 (Type: ACTIVE_COMPARATOR): Regular injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vortioxetine in Patients With Depression and Early Dementia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a primary diagnosis of recurrent Major Depressive Disorder (MDD) with onset before age of 55, diagnosed according to DSM-5®~* The current major depressive episode (MDE) must be confirmed using the Mini International Neuropsychiatric Interview (MINI).~* The patient has had the current MDE for \<6 months.~* The patient has a Montgomery and Åsberg Depression Rating Scale (MADRS) total score ≥26 at the Baseline Visit.~* The diagnosis of onset of dementia has occurred at least 6 months prior to screening and after already being diagnosed with MDD. The diagnosis of dementia must be documented in patient's medical records. When deemed necessary per investigator judgement of patient clinical status and early dementia, the patient must be accompanied by a caregiver to study visits.~* Patients with dementia associated with vitamin B12 or folate deficiency should not be enrolled.~* Patients with or without treatment for dementia can be enrolled. For patients on treatment for dementia, there must be no change in treatment during the study and patients must be on stable dose for at least 3 months prior to the Screening Visit.~* The patient has Mini Mental State Examination (MMSE) total score 20-24, inclusive.~Exclusion Criteria:~-The patient has any current psychiatric disorder or Axis I disorder (DSM-5® criteria), established as the primary diagnosis, other than MDD, as assessed using the Mini International Neuropsychiatric Interview (MINI) or another diagnostic interview.~Other in- and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Type: EXPERIMENTAL): 5 - 20 mg/day tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glucosamine Unum In Die [Once A Day] Efficacy (GUIDE) Trial: Glucosamine Sulfate in Patients With Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of knee osteoarthritis according to the clinical and radiological criteria of the American College of Rheumatology (ACR), with minimum symptom severity/characteristics~Exclusion Criteria:~* Standard exclusions apply

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with metastatic or locally advanced, unresectable breast cancer not amenable to curative treatment by surgery or radiotherapy~* Histological or cytological confirmation of ER+/ HER2- breast cancer~* Postmenopausal women~* No prior treatment for metastatic breast cancer~Exclusion Criteria:~* Patients with only non-measurable lesions other than bone metastases (e.g., pleural effusion, ascites, etc)~* Patients who had received prior hormonal or any other systemic therapy for metastatic breast cancer. Patients might have received prior neoadjuvant or adjuvant endocrine therapy. In the case of neoadjuvant or adjuvant NSAI (letrozole/anastrozole) therapy patients must have completed therapy at least 1 year prior to study enrollment.~* Previous treatment with mTOR inhibitors.~* Known hypersensitivity to mTOR inhibitors, e.g., sirolimus (rapamycin).~Other protocol-defined inclusion/exclusion criteria might apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus+letrozole/exemestane (first line and second line treatment) (Type: EXPERIMENTAL): Participants received everolimus in combination with letrozole as first-line treatment. Only participants who had disease progression in the first line setting (core phase) were offered second-line treatment (everolimus in combination with exemestane)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study for an Oral Contraceptive Containing Folate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Healthy women between 18 and 40 requesting oral contraception~Exclusion Criteria:~- The use of steroidal oral contraceptives, or any drug that could alter Oral Contraception metabolism will be prohibited during the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF) (Type: EXPERIMENTAL): 1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks
- Drospirenone (DRSP)/Ethinylestradiol (EE) (Type: ACTIVE_COMPARATOR): 1 tablet 0.020 mg EE/3.0 mg DRSP \[YAZ\] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ALV003 for the Treatment of Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of biopsy-proven celiac disease~* Adherence to a gluten-free diet~* TG2 antibody negative~* Signed informed consent~Exclusion Criteria:~* Active dermatitis herpetiformis~* History of IgE-mediated reactions to gluten~* Use of specific medications 6 months prior to entry~* History of alcohol abuse or illicit drug use~* Current untreated or GI disease~* Positive pregnancy test~* Received any experimental drug within 14 days of randomization~* Uncontrolled chronic disease or condition~* Uncontrolled complications of celiac disease~* Any medical condition, which could adversely affect participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ALV003 (Type: EXPERIMENTAL): ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
- Placebo comparator (Type: PLACEBO_COMPARATOR): Excipients for ALV003 absent the experimental compounds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent in writing available.~2. Willing and able to comply with all requirements of the study.~3. Male, 18 and 45 years (inclusive).~4. Subject has a body weight between 60 kg and 100 kg, extremes included.~5. BMI 18 to 27 kg/m2.~6. Non-smoker~7. Serum creatinine within reference range (≤1.2 mg/dL) and Cockroft-Gault Clearance \> 90 ml/min~8. Good general health as judged by the Investigator, as determined by medical history, physical examination, vital signs (systolic and diastolic blood pressure and pulse rate) and clinical laboratory parameters (clinical chemistry, hematology, and urinalysis)~Exclusion Criteria:~1. Clinically significant abnormalities in physical examination, vital signs or clinical laboratory parameters (according to the Investigator's judgment).~2. Serum glutamate oxaloacetate transaminase or glutamate-pyruvate transaminase \> 2-times above the upper limit of normal range.~3. Subject with Cockcroft-Gault clearance \< 90 ml/min.~4. Clinically significant history of cardiovascular disease or any known present cardiovascular disease.~5. History of clinically significant neurological, gastrointestinal, renal, hepatic, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders.~6. Office blood pressure at screening higher than 160/100 mmHg, or lower than 95/55 mmHg.~7. Office heart rate at screening after at least 5 minutes outside the range of 50- 99 beats per minute (inclusive).~8. Concomitant use of OTC medication within 1 week prior to dosing, except use of paracetamol (up to 2 g/day).~9. Participation in any other clinical study within 30 days prior to inclusion in this -

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Infusion (6 hours) of Saline
- VAS203 (Type: ACTIVE_COMPARATOR): Infusion (6 hours) of VAS203 (10 mg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurophysiological Targets for Cognitive Training in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizophrenia or schizoaffective disorder~* Age between 18 \& 70~* minimum of 30 days since discharge from last hospitalization~* minimum of 30 days since last change in psychiatric medications~* receiving mental health services~* no housing changes in the past 30 days~Exclusion Criteria:~* current diagnosis of alcohol or substance abuse~* history of brain trauma or neurological disease~* chart diagnosis of mental retardation or premorbid intelligence \< 70 based on Wechsler Test of Adult Reading (WTAR) full-scale estimated IQ~* auditory or visual impairment that would interfere with study procedures~  * a sample of 20 healthy community volunteers was also recruited according to these criteria and tested, without intervention, as a normative reference sample for MMN and P300 measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Auditory-Visual Train Order (Type: EXPERIMENTAL): 4 weeks (20 sessions) of auditory cognitive training (Brain Fitness) followed by 4 weeks (20 sessions) of visual cognitive training (Insight)
- Visual-Auditory Train Order (Type: EXPERIMENTAL): 4 weeks (20 sessions) of visual cognitive training (Insight) followed by 4 weeks (20 sessions) of auditory cognitive training (Brain Fitness)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Losartan in Decompensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* hospitalization for decompensated heart failure~* dobutamine dependence~* ejection fraction \< 0.45~* taking angiotensin-converting enzyme inhibitor~Exclusion Criteria:~* serum creatinine \> 3.0 mg/dL~* serum potassium \> 6.0 mEq/L~* systolic blood pressure \< 70 mm Hg~* aortic stenosis~* acute coronary syndrome in the previous 2 months

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Losartan (Type: EXPERIMENTAL): Losartan 50 mg bid orally
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 pill bid orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects, 12 to 65 years old~* Severe hemophilia B (FIX activity of ≤ 2%)~* Subjects who have received FIX products (plasma-derived and/or recombinant FIX) for \> 150 exposure days (EDs)~* No history of FIX inhibitor formation, no detectable inhibitors at Screening and no family history of inhibitors against FIX~* Written informed consent for study participation~* On-demand subjects only, who have experienced a minimum average of 2 non-trauma induced bleeding episodes requiring treatment with a FIX product during the previous 6 or 3 months~Exclusion Criteria:~* Known hypersensitivity to any FIX product or hamster protein~* Known congenital or acquired coagulation disorder other than congenital FIX deficiency~* HIV positive subjects with a CD4 count \< 200/mm3~* Low platelet count, kidney or liver dysfunction~* Recent life-threatening bleeding episode

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis (Type: EXPERIMENTAL): Routine weekly prophylaxis and episodic treatment for bleeding episodes. An individualized dosing interval may be tested in sub-group subjects during the 2nd part of the trial.~Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.
- On-demand (Type: EXPERIMENTAL): Episodic treatment for bleeding episodes during the first 6 months then switch to routine weekly prophylaxis for a further 6 months Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of pancreatitis~* Medically stable~* Able to give informed consent~Exclusion Criteria:~* Prior history of pancreatic resection~* Prior history of pancreatic duct drainage procedure~* Presence of a pancreatic stent~* Unstable cardiovascular disease~* Any contraindication to MRI procedure~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical IL-1-Ra for Treatment of Posterior Blepharitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of posterior blepharitis~* A negative urine pregnancy test result for women of childbearing potential~* Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation~* Normal lid position and closure~* Ability to understand and provide informed consent to participate in this study~* Willingness to follow study instructions and likely to complete all required visits.~Exclusion Criteria:~* History of Stevens-Johnson syndrome or ocular pemphigoid~* History of eyelid surgery~* Intra-ocular surgery or ocular laser surgery within 3 months~* History of microbial keratitis, including herpes~* Active ocular allergies~* Corneal epithelial defect \> 1mm2~* Use of topical steroids or Restasis within the past 2 weeks~* Use of tetracycline compounds (tetracycline, doxycycline, and minocycline) within the last month~* Use of isotretinoin (Accutane) within the past 6 months~* Have had any previous treatment with Anakinra (Kineret®) or any therapeutic agent targeted at IL-1 blockade~* Pregnant or lactating women~* Signs of current infection, including fever and current treatment with antibiotics~* Liver, renal, or hematologic disease~* The use of any other investigational drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm 1 (Type: ACTIVE_COMPARATOR): 2.5% IL-1Ra
- Placebo (Type: PLACEBO_COMPARATOR): Artificial Tear
- Treatment Arm 2 (Type: ACTIVE_COMPARATOR): 5% IL-1Ra

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety Study of Plecanatide

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients with documented diagnosis of IBS-C who:~* Completed plecanatide study SP304203-04 or SP304203-05, were compliant with the previous study's requirements, and did not experience any Serious Adverse Event (SAE) deemed related to study drug during the course of the previous study, OR~* Failed screening in study SP304203-04 or SP304203-05 due to diary noncompliance (an exclusion in the core study) or due to an administrative reason and is allowed to enter this study by notification from Sponsor or delegate.~Key Exclusion Criteria:~* Patient is unwilling or unable to: participate in the study for the required duration, understand and sign the informed consent form (ICF) and undergo all protocol related tests and procedures throughout the study.~* Female patient of childbearing potential with a positive urine pregnancy test on Day 1.~* Male and female patients of childbearing potential who do not agree to continue to use the method of birth control used in the core double-blind plecanatide study for the duration of this clinical trial.~* Patient has experienced a significant negative change in health status during the course of participation in the core double-blind plecanatide study or after completion of the study.~* In the opinion of the Investigator or Medical Monitor, it is not in the patient's best interest to participate in the study. The reason(s) for the patient's exclusion must be specified.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Plecanatide (Type: EXPERIMENTAL): Plecanatide 6.0 mg tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tegaderm vs. EyeGard for Eye Protection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Surgeries scheduled for anesthesia of any duration~Exclusion Criteria:~* Any patient that does not consent~* Any patient who has:~* Pre-existing eyelid erythema or other eyelid trauma~* Eyelid piercings~* Any surgery on the head, brain, neck, teeth, mouth, eyes or face~* Surgery in the prone position~* Patients \<18 years old

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TegadermTM on R eye, EyeGard® on L eye (Type: EXPERIMENTAL): Patients will get TegadermTM on Right eye, EyeGard® on Left eye
- TegadermTM on L eye, EyeGard® on R eye (Type: EXPERIMENTAL): Patients will get TegadermTM on Left eye, EyeGard® on Right eye

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete